Our product portfolio already consists of 7 Active Ingredients that enable us to pursue developments in a dozen therapeutic indications. All of our products are protected by patents for which we hold the exclusive operating licence.
• | Trials to be conducted in line with the development programme.
• | Trials ongoing (1st Pilocarpine dose-ranging study).
|Product||Indication||Dose Range||Phase 2||Phase 3||Running|
|Pilocarpine||Drug||Xerostomia associated with Gougerot-Sjögren syndrome or radiotherapy|
|Melatonin||Dietary supplement||Getting to sleep - sleep disorders See EFSA Journal 2011;9(6): 2241|
|Melatonin||Drug||Sleep disorders - Fibromyalgia|
|Statin||Drug||Treatment of hypercholesterolaemia and the prevention of myocardial infarction|
|Midazolam||Drug||Treatment of episodes of epilepsy and convulsions|
|Midazolam||Drug||Pre-anaesthetic and pre-medication treatment|
|Triptans||Drug||Acute treatment of migraine episodes|
|Setrons||Drug||Prevention of post-chemotherapy nausea|
|Doxylamine||Drug||Treatment of sleep disorders|
|Flunitrazapam||Drug||Treatment of severe sleep disorders|
|Other statins||Drug||Treatment of hypercholesterolaemia and the prevention of myocardial infarction|